Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study-Reference-Cited by-同舟云学术

Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study

Published:2015-08-21 Issue:9 Volume:90 Page:819-824
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Iriyama Noriyoshi¹,Fujisawa Shin²,Yoshida Chikashi³,Wakita Hisashi⁴,Chiba Shigeru⁵,Okamoto Shinichiro⁶,Kawakami Kimihiro⁷,Takezako Naoki⁸,Kumagai Takashi⁹,Inokuchi Koiti¹⁰,Ohyashiki Kazuma¹¹,Taguchi Jun¹²,Yano Shingo¹³,Igarashi Tadahiko¹⁴,Kouzai Yasuji¹⁵,Morita Satoshi¹⁶,Sakamoto Junichi¹⁷,Sakamaki Hisashi¹⁸

Affiliation:

1. Division of Hematology and Rheumatology, Department of Medicine; Nihon University School of Medicine; Tokyo Japan

2. Department of Hematology; Yokohama City University Medical Center; Kanagawa Japan

3. Department of Hematology; National Hospital Organization, Mito Medical Center; Ibaraki Japan

4. Division of Hematology and Oncology; Japanese Red Cross Society, Narita Red Cross Hospital; Narita Japan

5. Department of Hematology, Faculty of Medicine; University of Tsukuba; Ibaraki Japan

6. Division of Hematology, Department of Internal Medicine; Keio University School of Medicine; Tokyo Japan

7. Department of Hematology and Clinical Oncology; Kagawa Prefectural Central Hospital; Kagawa Japan

8. Department of Hematology; National Hospital Organization Disaster Medical Center; Tokyo Japan

9. Department of Hematology; Ohme Municipal General Hospital; Tokyo Japan

10. Division of Hematology, Department of Internal Medicine; Nippon Medical School; Tokyo Japan

11. Department of Hematology; Tokyo Medical University; Tokyo Japan

12. Department of Hematology; Japanese Red Cross Shizuoka Hospital; Shizuoka Japan

13. Division of Clinical Oncology and Hematology, Department of Internal Medicine; Jikei University School of Medicine; Tokyo Japan

14. Division of Hematology and Oncology; Gunma Prefectural Cancer Center; Gunma Japan

15. Department of Hematology; Tokyo Metropolitan Tama Synthesis Medical Center; Tokyo Japan

16. Department of Biomedical Statistics and Bioinformatics; Kyoto University Graduate School of Medicine; Kyoto Japan

17. Tokai Central Hospital; Gifu Japan

18. Hematology Division; Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Tokyo Japan

Funder

Epidemiological and Clinical Research Information Network (ECRIN)

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24096/fullpdf

Reference25 articles.

1. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

2. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia;Kantarjian;J Clin Oncol,2011

3. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system;Tauchi;Leuk Res,2011

4. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group;Yanada;J Clin Oncol,2006

5. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION);Jabbour;Blood,2014

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia;Haematologica;2023-01-26

2. Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?;Cancers;2022-09-13

3. Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukaemia patients during the first year of imatinib therapy;Gene;2022-03

4. NK Cells in Myeloproliferative Neoplasms (MPN);Cancers;2021-08-31

5. Unleashing the power of NK cells in anticancer immunotherapy;Journal of Molecular Medicine;2021-08-09